Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.76 |
| ▸ | CDK4 | P11802 | 1/20 | 0.76 |
| ▸ | CCND1 | P24385 | 1/20 | 0.76 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.76 |
| ▸ | CDK2 | P24941 | 1/20 | 0.76 |
| ▸ | GSK3B | P49841 | 3/20 | 0.75 |
| ▸ | PRKCA | P17252 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8166623 | 0.92 | CCNE2 (0.76) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL24622133 | 0.91 | CDK4 (0.74) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL30319849 | 0.87 | CCNE2 (1.00) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL5686048 | 0.87 | CCNE2 (1.00) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL3139155 | 0.86 | GSK3B (1.00) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7505472 | 0.85 | CCNE2 (0.78) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7054131 | 0.84 | CCNE2 (0.76) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7529336 | 0.84 | CCNE2 (0.77) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL8154922 | 0.84 | GSK3B (0.81) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL6942847 | 0.84 | CCNE2 (0.71) | CCNE2CDK4CCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1441772-A2 | POLYMER CONJUGATES OF PROTEIN KINASE C INHIBITORS | Nektar Therapeutics Al, Corporation (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030143185-A1 | Polymer conjugates of protein kinase C inhibitors | SHEARWATER CORPORATION | 2003-07-31 | — | — | US | disclosed |
| WO-2003037384-A2 | POLYMER CONJUGATES OF PROTEIN KINASE C INHIBITORS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-0915871-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-19 | — | — | EP | disclosed |
| US-5891901-A | ANTICARCINOGENIC AGENTS OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998004553-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F.HOFFMANN-LA ROCHE AG (CH) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143185-A1 | Polymer conjugates of protein kinase C inhibitors | PRKCH, PRKCI, PRKCA | CCNE2 2502/4885CDK4 387/4885CCND1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.